Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
Research in Oncology
2357-0687
2357-0695
12
1
2016
06
01
A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution Experience
2
9
EN
Dina
Salem
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
dinasalem70@yahoo.com
Ahmed
Essa
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
dinasalem70@gmail.com
Azza
Adel
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
azzaadel69@yahoo.com
Ahmed
Refaa
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
refae-2020@gmail.com
10.21608/resoncol.2016.587
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Aim: To assess the efficacy of reirradiation in locoregionally recurrent head and neck cancer (HNC) and </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">to describe results in our center in relation to other published data among similar group of patients. </span></span><br /> <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Methods: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">The medical records of 28 patients with HNC who received reirradiation with or without chemotherapy for loco-regional recurrence between 2005 and 2013 were reviewed. They were evaluated </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">for; toxicity profile, overall survival (OS) and progression free survival (PFS). </span></span></span></span><br /> <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Results: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">The median reirradiation dose was 50 Gy (range 40-60 Gy) and median radiation cumulative dose was 119 (range 113 -120). An overall response rate was seen in 36% of patients with only 3 patients showed complete response. The median OS was 9 months with 1-and 2-year survival rates being 34.1% </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">and 10.6%. The OS and PFS were significantly better in patients who were treated with chemotherapy </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">concomitant with radiation and received higher radiation dose. Grade 3 mucositis and skin reactions were seen in 24 % and 14% of patients, respectively. Conclusion: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Reirradiation appears to be feasible in patients with recurrent HNC treated previously with </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">radiation. The benefit of concurrent chemotherapy with reirradiation is expected. Our results are subject </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">to limitations from the retrospective nature of the analysis, the relatively small number, and improper selection of patients. </span></span></span></span></span></span></span></span>
Reirradiation,Recurrent head and neck cancer,Chemoradiotherapy
https://resoncol.journals.ekb.eg/article_587.html
https://resoncol.journals.ekb.eg/article_587_c9dc1a19a6306d4d48666d1f41703538.pdf
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
Research in Oncology
2357-0687
2357-0695
12
1
2016
06
01
Dosimetric Comparison of 3D Conformal Conventional Radiotherapy versus Intensity-Modulated Radiation Therapy both in Conventional and High Dose Radiation for Prostate Carcinoma
10
14
EN
Azza
Nasr
The Department of Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
nasrazza2@hotmail.com
Rasha
Elawady
Department of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt
10.21608/resoncol.2016.588
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Background: Radiotherapy plays an important role in the management of prostate cancer. There are ongoing efforts to deliver the optimum radiation dose to the prostate while minimizing it to at risk pelvic structures.</span></span>
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Aim: T<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">o compare the dose coverage of planning target volume (PTV) and organs-at-risk (OAR) between intensity-modulated radiation therapy (IMRT) and conventional three dimensiona</span></span><span style="font-family: Tahoma,Tahoma; font-size: small;"><span style="font-family: Tahoma,Tahoma; font-size: small;">l </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">conformal radiotherapy (3D-CRT) for the same plan of prostate cancer patients in both conventional dose and high dose. </span></span></span></span></span></span>
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Methods: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Plans of 15 prostate cancer patients with low- or intermediate risk, treated by 3D-CRT, were compared with IMRT to the same dose and to a higher dose. We used XIO- treatment planning system for 3D-CRT and Monaco treatment planning system for IMRT. </span></span></span></span></span></span></span></span>
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Results: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Mean and minimum dose to PTV were equal, but the mean maximum dose was significantly higher </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">in IMRT (72Gy) than 3D-CRT. Doses to critical organs in IMRT plans were lower than 3D-CRT, even in the increased dose of 80Gy. </span></span></span></span></span></span></span></span></span></span>
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Conclusion: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">IMRT is recommended as the standard of care in treatment of prostate carcinoma. Applying escalated dose is recommended. </span></span></span></span></span></span></span></span></span></span></span></span>
Prostate Cancer,Intensity-modulated radiation therapy,Escalated dose
https://resoncol.journals.ekb.eg/article_588.html
https://resoncol.journals.ekb.eg/article_588_7981efaeefbb1133810f20f24c578fff.pdf
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
Research in Oncology
2357-0687
2357-0695
12
1
2016
06
01
The Relation between Mean Platelet Volume/Platelet Count Ratio and Prognostic Factors in Patients with Advanced Non-Small Cell Lung Cancer
15
19
EN
Amal
Ibrahim
Department of Clinical Oncology, Faculty of Medicine, Assiut University, Assiut, Egypt
amal3774rayan@gmail.com
Ola
Abdel Fattah
Department of Clinical Oncology, Faculty of Medicine, Assiut University, Assiut, Egypt
olanabih1980@gmail.com
10.21608/resoncol.2016.589
Background: Identifying simple and reliable prognostic indicators in non-small cell lung cancer (NSCLC) is important to optimize its management. The mean platelet volume/platelet count (MPV/PC) ratio may be of prognostic value in some clinical conditions including NSCLC.<br />Aim: To investigate the relationship between MPV/PC ratio and some important prognostic factors in Egyptian NSCLC patients.<br />Methods: Retrospective study that included 69 patients with stage III/IV NSCLC in the period from January 2010 to December 2012. The complete blood picture done before starting treatment was the one considered for the calculation of MPV/PC. The relation between MPV/PC ratio and patients and disease characteristics was studied.<br />Results: More advanced stage was associated with lower average MPV/PC ratio. The average MPV/PC ratio was 0.45963 (95%CI: 0.38829- 0.53098) in patients with stage IIIA, 0.33873 (95%CI: 0.2854-0.39208) in stage IIIB and 0.32752 (95%CI: 0.28642- 0.36862) in stage IV (p=0.015).<br />Similarly, higher Eastern Cooperative Oncology Group performance status score was associated with lower MPV/PC ratio. The average MPV/PC ratio was 0.40949 (95%CI: 0.34959 – 0.46939) in patients with ECOG 1, 0.36369 (95%CI: 0.31009- 0.41724) in ECOG 2 and 0.28378 (95%CI: 0.24898 -0.31857) in ECOG 3 (p=0.004). Older patients had a significantly lower MPV/PC ratio (p=0.043).<br />Conclusion: Low MPV/PC is associated with poor prognostic factors in NSCLC such as advanced stage and poor performance status. Future clinical studies to evaluate the prognostic value of MPV/PC ration in NSCLC are warranted.
Non-Small Cell Lung Cancer,prognosis,Platelet volume/platelet count ratio
https://resoncol.journals.ekb.eg/article_589.html
https://resoncol.journals.ekb.eg/article_589_1e5a673ee1ec674166cdbf3eaddd8e28.pdf
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
Research in Oncology
2357-0687
2357-0695
12
1
2016
06
01
Study of Distribution of Bone Metastases in Metastatic Breast Cancer Patients Compared to Other Major Cancers
20
27
EN
Eman
Tawfik
Clinical Oncology Department, Faculty of Medicine, Menoufia University. Shibin El-Kom, Egypt
Ashraf
Zytoon
Clinical Radiology Department, Faculty of Medicine, Menoufia University, Shibin El-Kom, Egypt
ashradio@gmail.com
Suzy
Gohar
0000-0003-3250-5954
Clinical Oncology Department, Faculty of Medicine, Menoufia University. Shibin El-Kom, Egypt
dr.suzygohar@gmail.com
10.21608/resoncol.2016.590
Introduction: Metastatic bone disease is frequent in patients with advanced breast cancer. Although it is not specific for the detection of metastatic bony lesions, bone scan is a sensitive method. The pattern of distribution of bone metastases as detected by bone scan combined with clinical data may help in reaching diagnosis.<br />Methods: Technetium-99m-methylene diphosphonate skeletal scintigraphy was used for evaluation of distribution pattern of skeletal metastases in patients with breast carcinoma compared to other common cancers.<br />Results: Out of 134 patients with positive bone scan for skeletal deposits, the primary cancer was breast cancer in 81 patients, prostate in 24, lung in 12, liver in 8, urinary bladder in 6, and head and neck in 3.<br />Few metastases (≤ 3 deposits) were common in breast cancer, while extensive metastatic lesions (≥10 deposits) were more common in prostate cancer (50%). The most common locations of bone metastases in patients with breast cancer were the spine, pelvic bones, femora, and ribs, respectively.<br />In prostate cancer patients, spine was the most common site of metastases, especially the lumber region. In lung cancer patients, thoracic spine was the most common site of metastases, while pelvic bones were the most common site in liver cancer patients.<br />Conclusion: In breast cancer, the most frequent sites of involvement are the spine (especially lumber region), pelvis and axial skeleton, respectively. Spinal and sternal involvements are significantly more in breast cancer than in other malignancies.
Bone scan,breast cancer,Skeletal metastases
https://resoncol.journals.ekb.eg/article_590.html
https://resoncol.journals.ekb.eg/article_590_66a0e5990b0a3d158e05921025547511.pdf
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
Research in Oncology
2357-0687
2357-0695
12
1
2016
06
01
Hodgkin Lymphoma Presenting as Hemophagocytic Lymphohistiocytosis: A Case Report and Review of Published Cases
28
30
EN
Somaia
Mousa
0000-0003-2690-7041
Clinical Pathology Department, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
somaiamousa@kasralainy.edu.eg
10.21608/resoncol.2016.591
Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a serious syndrome that occurs in association<br />with malignancy, infections and autoimmune diseases.<br />Case presentation: A 30 years old female patient presented with fever, splenomegaly, pancytopenia,<br />hyperferritinemia, hypertriglyceridemia and hemophagocytosis in bone marrow aspirate. She was initially<br />diagnosed as HLH. Bone marrow biopsy revealed the presence of Hodgkin lymphoma.<br />Discussion: The most common HLH associated-malignancy is T/natural killer cell lymphoma and less<br />commonly diffuse large B-cell lymphoma. The combination of HLH and Hodgkin lymphoma is rare. A strong association between Hodgkin lymphoma associated HLH and Epstein Barr virus (EBV) infection has<br />been discussed in published case reports. Hodgkin lymphoma may be a cause of HLH and their relation with<br />EBV has to be investigated.
Hemophagocytic lymphohistiocytosis (HLH),Hodgkin Lymphoma,Epstein Barr virus (EBV)
https://resoncol.journals.ekb.eg/article_591.html
https://resoncol.journals.ekb.eg/article_591_0c238e18208db13b01d2f08038e96bfd.pdf